Phibro Animal Health Corporation PAHC R2KR3KPHARMA
Company Overview
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Why Investors Should Care
Generates a return on equity of 30.3%, reflecting efficient use of shareholder capital.
Net profit has compounded at 16.0% per year over the last five years.
Trades at a P/E of 16.4, below the sector median of 25.2.
Recent Developments
- Jun 2025 Revenue of $1.30B (+27.4% YoY); net profit $48.26M.
- Trailing 12 Months Year-on-year growth — revenue +10.3%, earnings +15.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.4%, profit CAGR 16.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.40% |
| 1 Year: | 10.30% |
Compounded Profit Growth
| 5 Years: | 16.04% |
| 1 Year: | 15.70% |
Stock Price Performance
| 1 Year: | +25.10% |
| 6 Months: | -19.59% |
| 3 Months: | +18.32% |
| 1 Month: | +8.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)62.10 · Neutral
P/E of 16.42 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.3%.
- Profit CAGR of 16.0% over 5 years.
CONS
- Trading 35.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PAHC Phibro Animal Health Corporation R2KR3KPHARMA | 38.25 | 16.42 | $805.88M | 1.35% | 10.35% | 30.34% | 5.40% | 16.04% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 214.66M | 232.71M | 239.62M | 232.52M | 244.65M | 245.67M | 231.35M | 249.94M | 263.22M | 260.43M | 309.26M | 347.82M | 363.89M | 373.91M | 383.54M |
| Gross Profit | 51.16M | 52.84M | 54.27M | 60.33M | 56.09M | 59.11M | 60.85M | 59.21M | 61.46M | 58.79M | 61.00M | 63.50M | 60.62M | 63.38M | 66.92M | 69.07M | 65.81M | 68.64M | 64.87M | 57.66M | 69.10M | 69.55M | 64.12M | 68.27M | 69.17M | 64.68M | 70.67M | 71.63M | 68.65M | 77.39M | 75.54M | 67.73M | 78.62M | 79.60M | 83.50M | 101.87M | 104.57M | 119.78M | 132.66M | 125.67M |
| Operating Income | 17.02M | 17.32M | 13.06M | 25.11M | 19.79M | 21.81M | 20.96M | 21.86M | 22.62M | 21.17M | 21.81M | 22.63M | 29.97M | 22.39M | 23.94M | 26.49M | 22.85M | 25.71M | 22.57M | 10.15M | 19.61M | 21.32M | 15.69M | 19.89M | 20.13M | 14.61M | 22.29M | 19.19M | 13.68M | 15.84M | 18.55M | -726.00K | 15.70M | 19.92M | 17.70M | 25.53M | 33.52M | 51.26M | 50.33M | 44.65M |
| Net Income | 2.30M | 6.37M | -17.64M | 18.93M | 14.25M | 16.70M | 10.40M | 18.75M | 30.18M | 18.58M | 12.18M | 13.42M | 23.64M | 15.89M | 7.03M | 19.84M | 16.31M | 14.75M | 14.85M | 2.52M | 11.89M | 13.50M | 12.30M | 12.80M | 12.16M | 6.53M | 17.46M | 17.69M | 3.86M | 7.21M | 10.04M | -8.02M | 1.27M | 8.40M | 6.97M | 3.19M | 20.88M | 26.53M | 27.46M | 24.02M |
| Diluted EPS | 0.08 | 0.21 | - | 0.48 | 0.36 | 0.42 | 0.26 | 0.47 | 0.75 | 0.46 | 0.31 | 0.34 | 0.59 | 0.39 | 0.17 | 0.49 | 0.40 | 0.36 | 0.37 | 0.06 | 0.29 | 0.33 | 0.30 | 0.32 | 0.30 | 0.16 | 0.43 | 0.44 | 0.10 | 0.18 | 0.25 | -0.20 | 0.03 | 0.21 | 0.17 | 0.08 | 0.51 | 0.65 | 0.67 | 0.59 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 654.10M | 653.15M | 691.91M | 748.59M | 751.53M | 764.28M | 819.98M | 828.00M | 800.35M | 833.35M | 942.26M | 977.89M | 1.02B | 1.30B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 656.86M | 679.65M | 704.59M | 896.27M |
| Gross Profit | 164.14M | 178.96M | 204.41M | 233.28M | 239.03M | 248.24M | 266.88M | 264.62M | 256.88M | 271.38M | 285.40M | 298.24M | 313.09M | 399.94M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 206.41M | 226.39M | 259.78M | 289.48M |
| Operating Income | 49.33M | 56.73M | 63.79M | 87.67M | 85.74M | 97.93M | 98.93M | 83.23M | 69.19M | 74.87M | 78.99M | 71.85M | 53.31M | 110.47M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 117.13M | 106.03M | 69.06M | 146.85M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 12.10M | 17.95M | 21.97M | 33.25M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | 72.33M | 54.07M | 10.92M | 67.99M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 23.15M | 21.46M | 8.50M | 19.73M |
| Net Income | 6.98M | 24.89M | -3.13M | 60.28M | 82.73M | 64.61M | 64.88M | 54.71M | 33.55M | 54.38M | 49.17M | 32.61M | 2.42M | 48.26M |
| Diluted EPS | - | 0.82 | -0.10 | 1.51 | 2.07 | 1.61 | 1.61 | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| R&D Expense | 7.19M | 6.64M | 8.21M | 9.51M | 11.03M | 9.44M | 10.00M | 12.09M | 13.74M | 17.76M | 20.83M | 24.39M | 29.19M | 23.73M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 474.14M | 472.32M | 493.32M | 607.84M | 623.40M | 671.68M | 726.67M | 784.10M | - | 931.70M | 971.40M | 982.18M | 1.36B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 566.23M | 585.72M | 601.00M | 810.61M |
| Cash & Equivalents | 48.60M | 53.90M | 27.37M | 11.82M | 29.22M | 33.60M | 56.08M | 29.17M | 57.57M | 36.34M | - | 74.25M | 41.28M | 70.61M | 68.04M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 259.16M | 277.57M | 265.91M | 444.43M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 166.54M | 163.48M | 169.45M | 227.98M |
| Total Liabilities | - | - | 543.08M | 457.17M | 463.69M | 517.36M | 472.24M | 486.73M | 510.66M | 595.90M | - | 669.26M | 688.89M | 725.54M | 1.08B |
| Current Liabilities | - | - | 115.40M | 112.44M | 111.33M | 108.78M | 115.80M | 143.22M | 154.23M | 157.24M | - | 190.83M | 176.00M | 204.15M | 293.47M |
| Long Term Debt | - | - | 297.67M | 286.42M | - | - | - | - | - | - | - | 417.93M | 452.54M | 458.29M | 702.43M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 470.48M | 509.97M | 525.46M | 761.55M |
| Total Equity | -69.07M | -88.23M | -68.94M | 15.15M | 29.63M | 90.48M | 151.16M | 184.95M | 216.01M | 188.20M | - | 262.44M | 282.51M | 256.64M | 285.68M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 40.50M | 40.50M | 40.50M | 40.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 37.22M | 98.39M | 70.01M | 47.17M | 59.35M | 48.31M | 31.65M | 13.31M | 87.59M | 80.12M |
| Investing Cash Flow | - | - | - | -82.79M | -21.94M | -84.61M | -14.13M | -120.39M | -18.58M | -22.58M | -74.02M | -48.19M | -288.69M |
| Financing Cash Flow | - | - | - | 50.38M | -53.74M | -11.78M | -4.11M | 40.94M | -17.00M | 16.34M | 26.99M | -6.77M | 207.13M |
| Dividends Paid | 3.00M | 25.00M | 15.60M | 15.71M | 15.83M | 16.07M | 18.59M | 19.42M | 19.43M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 25.1% | 27.4% | 29.5% | 31.2% | 31.8% | 32.5% | 32.5% | 32.0% | 32.1% | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| Operating Margin % | 7.5% | 8.7% | 9.2% | 11.7% | 11.4% | 12.8% | 12.1% | 10.1% | 8.6% | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% |
| Net Margin % | 1.1% | 3.8% | -0.5% | 8.1% | 11.0% | 8.5% | 7.9% | 6.6% | 4.2% | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| ROE % | -7.9% | -36.1% | -20.6% | 203.5% | 91.4% | 42.7% | 35.1% | 25.3% | 17.8% | - | 18.7% | 11.5% | 0.9% | 16.9% |
| ROCE % | - | 15.8% | 17.7% | 23.0% | 17.2% | 19.3% | 18.7% | 14.5% | 11.0% | - | 10.7% | 9.0% | 6.9% | 10.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.25% | 3.22M | $121.26M |
| 2 | FMR, LLC | 14.97% | 3.16M | $119.05M |
| 3 | State Street Corporation | 4.92% | 1.04M | $39.12M |
| 4 | Millennium Management Llc | 4.44% | 936.70K | $35.29M |
| 5 | Vanguard Capital Management LLC | 4.37% | 923.32K | $34.78M |
| 6 | Geode Capital Management, LLC | 3.11% | 657.35K | $24.76M |
| 7 | Lord, Abbett & Co. LLC | 3.10% | 653.30K | $24.61M |
| 8 | Dimensional Fund Advisors LP | 2.52% | 531.09K | $20.01M |
| 9 | Vanguard Portfolio Management LLC | 2.41% | 508.49K | $19.15M |
| 10 | Renaissance Technologies, LLC | 2.28% | 480.50K | $18.10M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PAHC
Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxObkRlbVVQcHAtMGxwRWtqUGZKRkc3LTRNcW55eUVfZGFCZ0U1ZGpEVTFhdE9uLTB5TlM2WXpOMDVnRl94QkpFeVlLWUo5SVA2b2ZMT2R1NzhtVk5tTkhPODhNLW9oT3AwbmVKclN3eEJCdGEwV1NRODU0V2VhNXdfdlFDYjRRX0VoOEtXSE…
PAHC or LMAT: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNYm56NzVpcllBZXZWZ1hIckxGd003S1FSS1B1NVVyMC11bHhhMlBSLWtLNVdwRnE1N2owc25VZEpETk84d0FTS3ktYmdvNDV0T25BT2U4SlpKblY1MzFWVnJjZVhSYk5nbVROZC01NDZZNEhZaG9YOE1PdE1FXzhwSm43ZG5jcGFtMGp4Mk…
Phibro Animal Health Corporation (PAHC) Stock Rises on Q4 2026 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOd0RoUGpRVlFISk1jbElOakhaOEJyeEl3bUVaR0JsaDRIY3hxRmxYOG5LbVlOamcxREp1YVdJdmlSeWtuVUx0MDBtaE85YWJ0NkdSTGRGeHV5QTUwbG5hRnV0UFlWSTAxXzVGS1VsdEtVTDkxLUUweTFsQW96ZVYwT3F6OW5xOHpGbU9HdX…
Phibro Animal Health (PAHC) Stock Shrugs Off Record Revenue As Margins Tighten - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMnF3Z3BrUkZRaDFNbUFuOHZsZW9jMlc3eGt3ZmsxcklwcW9oWkU2U2pjRXhMaDRua291bWNZOV95Sll5ZHZucVp4eXpOSDZoS25RMFNvdlJpMFI3NW9VOWZvNUpQNkM1a21HbTFDZk5kSHU0SnQtbzFCbkVWSnhfdlYxQVZLVldWaDJMN3…
Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - StockStory
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOdFJZMGZ0YW8xc1E4bnBxVXhlZVlxN1dKV3poV3JET3U4V1g1cDhfZXZ1VjdINUpvelU3RldYQWF4dENWQ2NWU25IRUh4VHYzdHFob3dUMVhlcUFBNy1oaS1OOGRDOG9jZHJXRUhyMk5zZVpidHZBVkVRN29PVWRNWlJRM29zWnAtMDJzZk…
Phibro Animal Health Corp (PAHC) Shares Surge 3.9% -- What GF Sc - GuruFocus
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOOVlNRmZTRExVQ19vY2xHNk5kUUNxZWxrWW5BX1E4bk1RTXRSZVRDSnk2OHByNlVIQkIxTXJIVDBWUWVuMkpsbW9FdjJ0U0xxbEN3Vm9IR2UxZXV2T25VTUFSY1A5dldmQWdVM1BLcDJqbVpOWUhKbWxGR1BYdmxPM29neC1IN1ViMXlMTD…
PAHC — Frequently Asked Questions
What is the current share price of Phibro Animal Health Corporation (PAHC)?
As of 2026-09-07 16:24 PDT, Phibro Animal Health Corporation (PAHC) trades at $38.25 on NasdaqGM. Its 52-week range is $28.31 to $59.14.
What is the market capitalisation of PAHC?
Phibro Animal Health Corporation (PAHC) has a market capitalisation of $805.88M on NasdaqGM.
What is the P/E ratio of PAHC?
PAHC trades at a trailing price-to-earnings (P/E) ratio of 16.42. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.84.
Does PAHC pay a dividend?
Phibro Animal Health Corporation (PAHC) currently offers a dividend yield of 1.35%.
What is the return on equity (ROE) of PAHC?
PAHC has a return on equity (ROE) of 30.34%. Its return on capital employed (ROCE) is 10.35%.
Is PAHC a good stock to buy?
This page provides a data-driven analysis of Phibro Animal Health Corporation (PAHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.